| Overall (n = 42) | Success (n = 30) | Failure (n = 12) | P value |
---|---|---|---|---|
Baseline characteristics | ||||
Age | 63 (57–72) | 60 (56–69) | 73 (61–78) | 0.009 |
Male (%) | 31 (74) | 22 (73) | 9 (75) | 0.99 |
Weight, kg | 85 (72–105) | 93 (74–115) | 79 (71–86) | 0.03 |
Height, m | 1.75 (1.67–1.80) | 1.75 (1.67–1.80) | 1.75 (1.66–1.76) | 0.41 |
BMI, kg/m2 | 27.7 (25.4–33.7) | 28.6 (26.0–37.1) | 27.3 (25.1–28.2) | 0.19 |
SAPS II | 41 (34–46) | 38 (33–46) | 45 (38–48) | 0.11 |
SOFA admission | 3 (2–5) | 3 (2–4) | 6 (3–8) | 0.01 |
SOFA intubation | 7 (6–8) | 7 (6–8) | 7 (6–9) | 0.61 |
Severity risk factor (%) | 31 (74) | 22 (73) | 9 (75) | 0.99 |
Hypertension, n (%) | 22 (52) | 15 (50) | 7 (58) | 0.74 |
Diabetes mellitus, n (%) | 7 (17) | 6 (20) | 1 (8) | 0.65 |
Cardiovascular disease, n (%) | 7 (17) | 4 (13) | 3 (25) | 0.39 |
Cancer, n (%) | 3 (7) | 3 (10) | 0 (0) | 0.55 |
Chronic respiratory disease n (%) | 11 (26) | 8 (27) | 3 (25) | 0.99 |
Chronic kidney disease, n (%) | 3 (7) | 3 (10) | 0 (0) | 0.55 |
BMI > 30, n (%) | 15 (36) | 14 (47) | 1 (8) | 0.03 |
Smokers, n (%) | 10 (24) | 10 (33) | 0 (0) | 0.04 |
Immunodeficiency, n (%) | 0 (0) | 0 (0) | 0 (0) | 0.99 |
Physiological variables | ||||
PaO2, mmHg | 83 (76–100) | 82 (75–99) | 89 (83–111) | 0.20 |
FiO2 | 0.60 (0.50–0.80) | 0.60 (0.56–0.80) | 0.50 (0.45–0.60) | 0.21 |
PaO2/FiO2, mmHg | 137 (118–172) | 133 (118–155) | 178 (145–197) | 0.05 |
SaO2, % | 95 (93–96) | 94 (93–96) | 95 (93–97) | 0.82 |
pH | 7.30 (7.22–7.34) | 7.28 (7.19–7.32) | 7.31 (7.24–7.36) | 0.39 |
PaCO2, mmHg | 50 (43–58) | 52 (45 -58) | 46 (42–58) | 0.51 |
HCO3−, mmol/L | 23.3 (21.4–24.4) | 23.6 (21.9–25.9) | 22.2 (20.0–23.1) | 0.01 |
Hb, g/L | 127 (110–135) | 125 (111–135) | 128 (109–136) | 0.65 |
Lactate, mmol/L | 1.1 (0.9–1.3) | 1.1 (0.8–1.3) | 1.2 (0.9–1.5) | 0.63 |
EtCO2 mmHg | 42 (37–48) | 42 (37–47) | 43 (34–52) | 0.83 |
PaCO2-EtCO2 mmHg | 7 (1–11) | 5 (1–16) | 7 (2–10) | 0.93 |
Aa-gradient, mmHg | 255 (200–345) | 265 (241–368) | 172 (164–254) | 0.04 |
VR | 1.7 (1.3–2.2) | 1.7 (1.2–2.2) | 1.8 (1.4–2.4) | 0.59 |
VD/VT HB | 0.59 (0.51–0.68) | 0.58 (0.50–0.68) | 0.65 0.56–0.73) | 0.15 |
Ventilatory data | ||||
Vt/PBW, ml/kg | 6.7 (6.0–7.0) | 6.6 (6.1–7.0) | 6.8 (6.0–6.9) | 0.85 |
RR, min−1 | 20 (17–22) | 18 (16–22) | 22 (20–24) | 0.13 |
PEEP, cmH2O | 12 (10–14) | 13 (10–14) | 12 (10–12) | 0.09 |
Pplat, cmH2O | 25 (22–28) | 25 (22–28) | 22 (21–27) | 0.23 |
∆P, cmH2O | 13 (10–14) | 13 (10–14) | 12 (10–14) | 0.65 |
CRS, ml/cmH2O | 36.4 (29.3–42.5) | 36.4 (30.0–40.0) | 36.1 (28.5–44.0) | 0.93 |
Hemodynamics data | ||||
HR, min−1 | 87 (70–100) | 84 (73–108) | 89 (65–99) | 0.41 |
MAP, mmHg | 74 (67–84) | 73 (68–82) | 76 (66–86) | 0.48 |
Norepinephrine, µcg/kg/min | 0 (0–0.07) | 0 (0–0.06) | 0.02 (0–0.1) | 0.41 |
Outcome data | ||||
LoS Hospital, days | 29 (23–40) | 29 (24–40) | 24 (12–29) | 0.06 |
LoS ICU, days | 18 (13–27) | 18 (13–25) | 23 (10–29) | 0.97 |
Ventilation days | 15 (10–20) | 14 (11–17) | 20 (9–24) | 0.24 |
Ventilator free days at Day 28 | 11 (0–17) | 14 (11–17) | 0 (0–1) |  < 0.001 |